Navigation Links
Novogen Announces Establishment of Global Collaboration to Drive The Development of Drugs to Treat Brain Cancer
Date:12/20/2013

SYDNEY, Dec. 20, 2013 /PRNewswire/ -- Novogen Limited, an oncology drug development company, announced today the signing of a Sponsored Research Agreement with Cornell University. The Weill Cornell Medical College (WCMC) in New York will become the cornerstone of a collaboration across Europe, US, Asia and Australia involving universities and biotechnology companies seeking a treatment capable of delivering long-term remission for the main form of primary brain cancer, glioblastoma multiforme (GBM).

(Logo:  http://photos.prnewswire.com/prnh/20131220/NY36990LOGO )

The research program is focused on the super-benzopyran drug, Trilexium (Trx).

The brain cancer program parallels that of the Company's efforts in the area of ovarian cancer through its joint venture, CanTx Inc, with Yale University.

CanTx has identified a Trilexium derivative (Trx-1) as having equipotent killing ability of both ovarian cancer stem cells and ovarian cancer somatic cells, raising the prospect for the first time of being able with the one agent to kill the full hierarchy of cells within an ovarian cancer. The CanTx strategy is to bring Trx-1 into the clinic in the near-term as a generic treatment for late-stage ovarian cancer, but then to use the Trx pharmacophore to create a panel of drugs capable of killing ovarian cancer cells with specific genotypes, a further unique feature of this technology platform.

The brain cancer program has the same R&D and commercial objectives. The near-term goal is to bring Trilexium into the clinic as a generic treatment for GBM that has failed to respond to Temozolomide, the only drug approved for GBM. The longer-term goal is to identify a panel of drugs capable of providing a personalized approach to GBM chemo
'/>"/>

SOURCE Novogen Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novogen Files Suite of Patents for Anti-Tropomyosin Drug Technology
2. Novogen Launches Joint Venture Aimed At Developing Drugs to Fight Ovarian Cancer
3. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
4. As Released on 30 December, 2011: Novogen Modifies ADR Program and Makes Further Investment Into Marshall Edwards
5. Symphogen Announces the Appointment of Annika Espander Jansson as Non-Executive Director
6. Lineagen Announces $3.5 Million Series C Round and Close of Series B Financing
7. Amgen Announces Positive Top-Line Results From Phase 3 MENDEL-2 Trial Of Evolocumab (AMG 145) In Patients With High Cholesterol
8. Asmacure Announces Clinical Update for ASM-024 DPI in Two Phase 2 Trials
9. China Cord Blood Corporation Announces Results of 2013 Annual General Meeting
10. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
11. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... PMG Research, Inc. announced today the formation ... of sites that provide clinical research services to pharmaceutical companies ... through its partnerships with large physician practices and integrated health ... in the Southeastern United States and spans over 60 physician ... will be held by: Dr. Robert Holmes, MD, of ...
(Date:11/26/2014)... Continuing its award-winning streak, Nerium International, the leader ... for outstanding creative achievement by its marketing and communication ... organization’s top honor, in the Branding category for its ... of this year. The event showcased top speakers and ... awarded a Gold MarCom Award in the Special Events ...
(Date:11/26/2014)... Boston, MA (PRWEB) November 26, 2014 ... and collaboration company is proud to announce that Darren ... Development and Sales. Darren will drive the ... and positive customer experience. , Darren brings ... He has held key roles in channel operations, from ...
(Date:11/26/2014)... Nov. 25, 2014 Bio-Techne Corporation (NASDAQ: ... Robert Gavin to serve in a newly ... Platforms Division.  Mr. Gavin will be responsible for managing ... includes the ProteinSimple business acquired in July 2014 and ... San Jose, California -based ProteinSimple develops and commercializes ...
Breaking Biology Technology:PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2SoundConnect Appoints Director of Channel Development & Sales 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... ... ... Agricultural improvements will play a key role in tackling Africa’s crucial problems of hunger ... during the World Economic Forum on Africa. , , , , ,“Local infrastructure that ...
... May 6, 2010 Oramed,Pharmaceuticals Inc. (OTCBB: ORMP), a developer ... Phase 2b non-FDA,clinical trial of its flagship oral insulin capsule, ORMD-0801. ... ... Africa evaluated responses of 29 Type 2 diabetes patients,to ORMD-0801. ...
... ... ... -- ProRepro today announced it has become an Autodesk authorized value-added reseller (VAR). ... California. ProRepro’s qualified staff demonstrates in-depth technical and industry knowledge and a commitment to ...
Cached Biology Technology:DuPont Leader: Agricultural Improvements Key to Meeting Growing Food, Water Needs in Africa 2Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients 2Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients 3ProRepro Becomes a Value-Added Reseller for Autodesk 2
(Date:11/5/2014)... de Janeiro, Brazil -Individuals show great diversity in their ... males and females greatly differ in their perceptual evaluation ... of smell tests. , Sex differences in ... behaviors and may be connected to one,s perception of ... emotions. Thus, women,s olfactory superiority has been suggested to ...
(Date:11/4/2014)... University School of Medicine announced today that it ... funded by the Bill & Melinda Gates Foundation. ... Gynecology and Reproductive Sciences; and Vice Chair of ... of Medicine will pursue an innovative global health ... to Assess Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) ...
(Date:11/4/2014)... , November 4, 2014   ... vertical market growth   Fuel3D , a ... closed a funding round totaling $6.4 million (£4 million). This ... funding secured earlier this year and paves the way for ... 2015. The funding round was led by Chimera ...
Breaking Biology News(10 mins):The female nose always knows: Do women have more olfactory neurons? 2Temple University School of Medicine receives Grand Challenges Explorations grant 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... John Shelnutt and Yujiang Song have discovered a better way ... a new process that produces novel hollow platinum nanostructures. , ... issue of the German chemical journal Angewandte Chemie Int. Ed. ... "hot paper" on the journal's web site. , Sandia ...
... and a common heavy metal are unable to obtain ... to a new study presented at The American Physiological ... showed how cadmium, a heavy metal, reduces the oyster's ... vulnerable during the summer when water temperatures rise. Half ...
... the University of Minnesota, Extension food scientist Joellen Feirtag ... activation system that disinfects, cleans food and wipes out ... not new, this system, developed by a team of ... solution that won't cause deterioration or off-flavors when sprayed ...
Cached Biology News:Sandia researchers discover way to see how a drug attaches to a cell 2Rising ocean temperatures, pollution have oysters in hot water 2Rising ocean temperatures, pollution have oysters in hot water 3Rising ocean temperatures, pollution have oysters in hot water 4
... HM-4000 Multidizer is designed with a ... orbital, rotating - all in one unit. ... Two independently operating compartments allow for hybridization ... or motion , The upper chamber ...
... Jouan MSC series of Class II ... conditions and certification to the world's ... ensures that the cabinets cannot be ... Natural lighting, low noise and arm ...
... RC Sensitive Bio (for heat-labile and very ... respond to specific applications of molecular biology ... of heat-labile samples. The RC systems can ... traps and a wide selection of rotors ...
... HB-500 Minidizer is a personal desktop unit ideal ... space requirements. , Rotation speed set at ... to 80o C , Bottle capacity of ... or 15 ml conical ,plastic bottles , ...
Biology Products: